About Heartseed
Heartseed is a publicly listed company based in Shinjuku (Japan) founded in 2015 by Keiichi Fukuda. Developer of myocardial regenerative medicine for treating heart diseases. Heartseed has raised $76.73 million across 4 funding rounds from investors including SBI Group, Sumitomo Mitsui Trust Holdings and JMDC. The company has 39 employees. Its chief executive, as recorded, is Keiichi Fukuda. Its website heartseed.jp draws about 10 thousand monthly visits. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Heart Failure.
Company details
Heartseed was founded in 2015 in Shinjuku City, Japan, within the biotechnology sector focused on regenerative medicine. Operations center on creating therapies from human induced pluripotent stem cells to address heart conditions. The lead product, HS-001, consists of allogeneic iPS cell-derived regenerated myocardium aimed at treating heart failure. Development efforts emphasize clinical applications for myocardial regeneration.
- Headquarters Shinjuku, Japan
- Employees 39
- Founders Keiichi Fukuda
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website heartseed.jp
- Social LinkedIn
- Legal Name Heartseed, Inc.
- Annual Revenue$16.53 M (USD)196.94as on Dec 31, 2025
- Net Profit$1.04 M (USD)as on Dec 31, 2025
- EBITDA$1.78 M (USD)as on Dec 31, 2025
- Total Equity Funding$76.73M (USD)
in 4 rounds
- Latest Funding Round$14.41M (USD), Series D
May 2023
- InvestorsSBI Group
& 19 more
- Employee Count39
Funding Insights of Heartseed
Heartseed has successfully raised a total of $76.73M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $14.41 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76.73M
- Total Rounds 4
- Last Round Series D — $14.41M
- First Round $25.79M
(Nov 2019)
- Investors Count 20
All 4 funding rounds of Heartseed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $14.41M | Series D | – | Japan Co-Invest, Arcus Invest | |
| Jun 2021 | $36.53M | Series C | – | UTokyo Innovation Platform, Medical Incubator Japan | |
| Mar 2020 | Series B | – | MEDIPAL | – | |
| Nov 2019 | $25.79M | Series B | – | JMDC, Gene Techno Science |
20 investors in total: 19 institutional and 1 angel.
Investors in Heartseed
Heartseed has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include SBI Group, Sumitomo Mitsui Trust Holdings and JMDC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| japanco-investiv.tcc.mode | ||||
| koeitecmocapital.tcc.mode | ||||
| nikon-sbiinnovationfund.tcc.mode | ||||
| smbc-vc.co.jp | ||||
Accelerator and venture capital services are provided by UTokyo-backed platform. | utokyo-ipc.co.jp | Bunkyo, Japan | ||
Investment in innovative healthcare startups is facilitated by this company. | medicalincubatorjapan.com | Japan | ||
Stage-agnostic investments in Japanese tech and life sciences are made. | 2015 | keio-innovation.co.jp | Tokyo, Japan | |
Venture capital firm investing in biotech, adtech sectors | nissay-cap.co.jp | Chiyoda City, Japan | ||
| astellasventure.com | ||||
Venture capital funds are managed to support unlisted companies' growth. | sbinvestment.co.jp | Minato City, Japan |
Investor details for Heartseed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Heartseed
2 people are tracked at Heartseed (2 in leadership); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Keiichi Fukuda | Founder & CEO | Leadership |
Kikuo Yasui | Chief Operating Officer | Leadership |
Complete people profiles for Heartseed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Heartseed
Heartseed is a publicly listed company on the TSE with ticker symbol 219A in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jul 2024
- Listed onTSE: 219A
- Listed entityHeartseed, Inc.
- Exchange sectorHealth technology
- ISINJP3765140003
- Share price2,738.00 JPY (+1.44% on the day) · 2026-10-14
- Market capitalisation61,832,473,137.00 JPY
- Price to earnings70.0
- Volume (last session)345,200
Financials of Heartseed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.59B JPY | 163.4M JPY | 278.7M JPY |
| 2024 | 873.6M JPY | -812.7M JPY | -997.0M JPY |
| 2023 | 344.7M JPY | -1.47B JPY | -1.45B JPY |
| 2022 | 499.1M JPY | -1.41B JPY | -1.46B JPY |
Detailed financial statements for Heartseed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Heartseed
4 dated milestones of Heartseed across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Heartseed is founded.
- Funding First funding round of $25.8M.
- Funding Latest funding round, Series D, of $14.4M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Heartseed
The website of Heartseed (heartseed.jp) receives about 10K visits a month and ranks #1,221,896 among all websites worldwide, #1,539 in Biotechnology and Pharmaceuticals.
- Monthly visits10K
▼ 45.9% vs previous month
- Unique visitors6.5K
per month
- Global rank#1,221,896
among all websites
- Category rank#1,539
Health · Biotechnology and Pharmaceuticals
- Bounce rate22%
- Pages per visit2.9
- Average visit3 min 35 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Heartseed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| yakuji.co.jp | 100% | #354,518 | View details | ||
finance.yahoo.co.jp | finance.yahoo.co.jp | 29% | #530 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Heartseed
Complete news archive for Heartseed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Heartseed
Heartseed was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Heartseed is headquartered in Shinjuku, Japan. It is registered at Shinjuku, Tokyo, Japan.
Keiichi Fukuda is the CEO of Heartseed, as recorded in our data. They have also founded this company.
Heartseed is a funded company, having raised a total of $76.73M across 4 funding rounds to date. The company's 1st funding round was a Series B of $25.79M, raised on Nov 2019.
Heartseed has 39 employees.
Annual revenue of Heartseed is $16.53M as on Dec 31, 2025.
Heartseed was founded in 2015 in Shinjuku City, Japan, within the biotechnology sector focused on regenerative medicine. Operations center on creating therapies from human induced pluripotent stem cells to address heart conditions. The lead product, HS-001, consists of allogeneic iPS cell-derived regenerated myocardium aimed at treating heart failure. Development efforts emphasize clinical applications for myocardial regeneration.
Yes, Heartseed is publicly traded on TSE under the ticker symbol 219A.
Heartseed has 20 investors. Key investors include SBI Group, Sumitomo Mitsui Trust Holdings, JMDC, Medipal, and Keio Innovation Initiative.